2017-09-11 19:47:15 UTC

Share Your Cutting-Edge IBD Research

Sept. 11, 2017

The processing fee for oral and/or poster presentation is being waived. Submissions are due by October 31 at 9 p.m. ET.

Join the Crohn's & Colitis Foundation and the American Gastroenterological Association (AGA) for the inaugural Crohn's & Colitis Congress™, the must-attend meeting for all inflammatory bowel disease (IBD) professionals, taking place January 18-20, 2018 in Las Vegas.

  • Build a powerful network and share solutions with thought-leaders in IBD.
  • Learn together as one multi-disciplinary care team.
  • Determine best practices at every stage of the patient’s disease journey.
  • Discover cutting-edge basic, translational and clinical research in the IBD space.
  • Improve skills and patient outcomes.
  • Explore new technologies and products from IBD-related exhibitors.
  • Earn CME credits and MOC points.

Share your cutting-edge basic, translational and clinical research discoveries in IBD with the top leaders in the field. Submit for oral and/or poster presentation for free. The processing fee for the inaugural year of the Crohn’s & Colitis Congress is being waved. All accepted abstracts will be co-published in Gastroenterology and Inflammatory Bowel Diseases.

Abstract submissions end October 31 at 9 p.m. ET. Notifications will be sent December 4. Late-breaking abstracts will be accepted from November 28-December 8.

Travel Grants Available
Fellows, nurses, and advanced practice providers are encouraged to submit abstracts for oral presentation and be considered for a travel grant. Visit www.crohnscolitiscongress.org/abstracts.


More on Crohn's Disease

Crohn's & Colitis Congress™ (A Partnership of the Crohn's & Colitis Foundation and American Gastroenterological Association)

Jan. 18, 2018

Expand your knowledge, network with IBD leaders, spark innovative research and get inspired to improve patient care.

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months

Oct. 22, 2017

We investigated whether serum trough levels of vedolizumab, during the induction phase can determine whether patients need additional doses within 6 months.

Healing of Tonsillar Crohn’s Disease With Infliximab

Oct. 22, 2017